The DOI matches its Crossref record.
Methotrexate pharmacokinetics and prognosis in osteosarcoma.
Abstract
PURPOSE: The influence of methotrexate (MTX) pharmacokinetic parameters on the efficacy of high-dose MTX (HDMTX) in osteosarcoma was analyzed. PATIENTS AND METHODS: MTX serum peak values from 198 patients in 1,703 treatment courses and more detailed pharmacokinetic data from 185 patients in 1,045 treatment courses from the Cooperative Osteosarcoma Study Group (COSS) studies COSS-80, COSS-82, and COSS-86 were investigated. RESULTS: A mean threshold peak level of > or = 1,000 mumol/L for the repeated MTX courses of individual patients was found to correlate significantly to prognosis in study COSS-80 (18% v 64% actuarial 10-year disease-free survival [DFS], P = .0001). Six courses of HDMTX per patient who achieved peak values > or = 1,000 mumol/L were found to be sufficient for a full effect to be seen in DFS in COSS-80. The MTX peak level was found to correlate closely to the area under the curve (AUC). However, AUC was a less powerful determinator of prognosis than the mean threshold MTX peak value. In patients who received cisplatin (DDP) as one of the additional drugs to MTX, the peak values and AUC were significantly increased (1,396 v 1,276 mumol/L, P = .011; 6,684 v 5,820 h.mumol/L, P < or = .002) and only a few patients (6%) did not achieve mean threshold MTX peak values. In addition, following restriction of hydration fluid after the MTX infusion from 4.5 to 3.0 L/m2 per 24 hours, the early MTX half-life (t1/2) and the AUC, but not the MTX peak value, were significantly increased (3.4 v 3.05 hours, and 6,760 v 5,998 h.mumol/L, respectively, P < or = .002). CONCLUSION: MTX pharmacokinetics significantly influence the efficacy of MTX in osteosarcoma. Individual adaptation of the MTX dose to ensure a threshold peak serum level > or = 1,000 mumol/L does not seem necessary at a fixed dose of 12 g MTX/m2, restriction of hydration fluid to 3 L/m2 per 24 hours, and concomitant use of DDP within the drug regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 383
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics
Paci, A., Veal, G., Bardin, C., Levêque, D., Widmer, N., Beijnen, J., Astier, A., & Chatelut, E. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.014 · Cited by 260
Osteosarcoma: Review of the Past, Impact on the Future. The American Experience
Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_12 · Cited by 252
Walling, J. (2006) · Investigational New Drugs · doi:10.1007/s10637-005-4541-1 · Cited by 182
Metadata
- Authors
- Graf, N., Winkler, K., Betlemovic, M., Fuchs, N., & Bode, U.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-07
- Volume
- 12
- Issue
- 7
- Pages
- 1443-1451
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1810454109
- Cited by
- 176
- References
- 0
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methotrexate pharmacokinetics and prognosis in osteosarcoma. https://app.cochat.ai/papers/10.1200/jco.1994.12.7.1443
- The paper
- Graf, N., Winkler, K., Betlemovic, M., Fuchs, N., & Bode, U. (1994). Methotrexate pharmacokinetics and prognosis in osteosarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.7.1443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.